Biologic therapy for eosinophilic asthma • Mepolizumab (Nucala) • Anti-lL-5, 100 mg SQ q4 weeks • Peripheral eosinophils >150/microL, need VZV vaccine • Reslizumab (Cinqair) • Anti-lL-5, 3 mg/kg IV q4 weeks • Peripheral eosinophils >400/microL • Benralizumab (Fasenra) • Anti-lL-5 receptor, 30 mg SQ q4 weeks x3 doses -> q8 weeks • Peripheral eosinophils >300/microL • Dupilumab (Dupixent) • Anti-lL-4/13 receptors, 600 mg SQ x 1 -> 300 mg q2 weeks • Peripheral eosinophils >150/microL Dr. Avraham Z. Cooper, MD @AvrahamCooperMD #eosinophilic #asthma #Biologic #therapy #Medications #pharmacology #pulmonary #management
